Publication

Fibrosis markers, hip fracture risk, and bone density in older adults

Downloadable Content

Persistent URL
Last modified
  • 05/20/2025
Type of Material
Authors
    Joshua Barzilay, Emory UniversityPetra Buzkova, University of WashingtonJorge R. Kizer, Albert Einstein College of MedicineLuc Djousse, Brigham & Womens HospitalJoachim H. Ix, University of California San DiegoHoward A. Fink, Veterans Affairs Medical CenterDavid S. Siscovick, New York Academy of ScienceJane A. Cauley, University of PittsburghKenneth J. Mukamal, Beth Israel Deaconess Medical Center
Language
  • English
Date
  • 2016-02-01
Publisher
  • Springer London
Publication Version
Copyright Statement
  • © 2015, International Osteoporosis Foundation and National Osteoporosis Foundation.
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 27
Issue
  • 2
Start Page
  • 815
End Page
  • 820
Grant/Funding Information
  • This work was also funded in part by R01 HL094555 from the National Heart, Lung, and Blood Institute (to Drs. Djoussé, Ix, Kizer, and Mukamal).
  • This research was supported by contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS).
Abstract
  • Summary: We examined whether blood levels of two markers of fibrosis (transforming growth factor beta one (TGF-β1) and procollagen type III N-terminal propeptide (PIIINP)) are related to hip fracture risk and to bone mineral density (BMD). TGF-β1 levels were associated with lower hip fracture risk in women and with lower BMD in men. PIIINP levels were not associated with either outcome. Introduction: TGF-β1 serves several roles in bone formation and resorption. A consequence of TGF-β1 activation is the production of PIIINP, a marker of collagen III deposition. Here, we explore whether these two biomarkers are related to incident hip fracture and bone mineral density (BMD) and whether their associations are modified by systemic inflammation, as measured by C-reactive protein (CRP) levels. Methods: Participants were from the Cardiovascular Health Study (mean age 78 years; mean follow-up 8.3 years). We included 1681 persons with measured levels of TGF-β1 (149 hip fractures) and 3226 persons with measured levels of PIIINP (310 hip fractures). Results: Among women, higher TGF-β1 levels were associated with lower hip fracture risk (HR, per doubling, 0.78 [95 % CI 0.61, 0.91]). Among men, TGF-β1 levels were associated with hip fracture risk in a non-linear manner, but among those with elevated CRP levels, doubling was associated with increased risk of fracture (HR 2.22 [1.20, 4.08]) (p = 0.02, interaction between low and high CRP and TGF-β1 on fracture risk). TGF-β1 levels had no significant association with total hip or total body BMD in women but were significantly associated with lower BMD in men. There were no associations of PIIINP levels with hip fracture risk or BMD in men or women. Conclusions: TGF-β1 levels appear to be associated with bone-related phenotypes in a sex-specific manner. The reasons for these differences between men and women regarding TGF-β1 levels and hip fracture risk and bone density require further investigation.
Author Notes
  • Corresponding authors: Joshua Barzilay M.D., 3650 Steve Reynolds Blvd, Duluth, GA 30096. Tel 770 931 6094, Fax 770 931 6365, joshua.barzilay@kp.org
Keywords
Research Categories
  • Health Sciences, Medicine and Surgery
  • Biology, Anatomy

Tools

Relations

In Collection:

Items